Yasuko Iwakiri – 13 February 2017

Aynur Unalp‐Arida, Constance E. Ruhl – 13 February 2017 – Fatty liver disease is common in the United States and worldwide due to changing lifestyles and can progress to fibrosis and cirrhosis contributing to premature death. We examined whether liver fibrosis scores were associated with increased overall and disease‐specific mortality in a United States population–based prospective survey with up to 23 years of linked‐mortality data. Data were analyzed from 14,841 viral hepatitis–negative adult participants in the third National Health and Nutrition Examination Survey, 1988‐1994.

Lucy Golden‐Mason, Hugo R. Rosen – 13 February 2017 – Glycan‐binding proteins, which include galectins, are involved at all stages of immunity and inflammation, from initiation through resolution. Galectin‐9 (Gal‐9) is highly expressed in the liver and has a wide variety of biological functions in innate and adaptive immunity that are instrumental in the maintenance of hepatic homeostasis. In the setting of viral hepatitis, increased expression of Gal‐9 drives the expansion of regulatory T cells and contraction of effector T cells, thereby favoring viral persistence.

Hao Wang, Peng An, Enjun Xie, Qian Wu, Xuexian Fang, Hong Gao, Zhuzhen Zhang, Yuzhu Li, Xudong Wang, Jiaying Zhang, Guoli Li, Lei Yang, Wei Liu, Junxia Min, Fudi Wang – 13 February 2017 – Ferroptosis is a recently identified iron‐dependent form of nonapoptotic cell death implicated in brain, kidney, and heart pathology. However, the biological roles of iron and iron metabolism in ferroptosis remain poorly understood. Here, we studied the functional role of iron and iron metabolism in the pathogenesis of ferroptosis.

Dana J.T. Bruden, Brian J. McMahon, Lisa Townshend‐Bulson, Prabhu Gounder, Jim Gove, Julia Plotnik, Chriss Homan, Annette Hewitt, Youssef Barbour, Philip R. Spradling, Brenna C. Simons, Susan McArdle, Michael Bruce – 13 February 2017 – Long‐term prospective studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical for assessing the potential impact of HCV treatment.

Filipe S. Cardoso, Rui Pereira, Gonçalo Alexandrino, Luís Bagulho – 13 February 2017

Lucy Golden‐Mason, Hugo R. Rosen – 13 February 2017 – Glycan‐binding proteins, which include galectins, are involved at all stages of immunity and inflammation, from initiation through resolution. Galectin‐9 (Gal‐9) is highly expressed in the liver and has a wide variety of biological functions in innate and adaptive immunity that are instrumental in the maintenance of hepatic homeostasis. In the setting of viral hepatitis, increased expression of Gal‐9 drives the expansion of regulatory T cells and contraction of effector T cells, thereby favoring viral persistence.

Guofeng Chen, Cheng Wang, Jing Chen, Dong Ji, Yudong Wang, Vanessa Wu, Johan Karlberg, George Lau – 13 February 2017 – There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan‐oral direct‐acting antiviral agents (DAAs).

Lionel Arrivé, Sanaâ Mouhadi – 13 February 2017

Raquel Yotti, Cristina Ripoll, Yolanda Benito, Maria Vega Catalina, Jaime Elízaga, Diego Rincón, Francisco Fernández‐Avilés, Javier Bermejo, Rafael Bañares – 13 February 2017 – An accurate evaluation of cardiac function in patients with cirrhosis remains a challenge. We used robust echocardiographic indices to characterize left ventricular (LV) systolic function and its relationship to activation of the sympathetic nervous system and inflammation in 59 patients with cirrhosis and 59 age‐matched controls.